PGNY vs. ACXP
PGNY (Progyny, Inc.) and ACXP (Acurx Pharmaceuticals, Inc.) are both stocks. Both are in the Healthcare sector — PGNY in Health Information Services, ACXP in Biotechnology. Over the past 3 years, PGNY returned -10.45%/yr vs -69.14%/yr for ACXP. At a 0.09 correlation, their price movements are largely independent.
Performance
PGNY vs. ACXP - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, PGNY achieves a 2.34% return, which is significantly higher than ACXP's -39.36% return.
PGNY
- 1D
- 0.77%
- 1M
- 5.63%
- YTD
- 2.34%
- 6M
- -2.52%
- 1Y
- 25.26%
- 3Y*
- -10.45%
- 5Y*
- -15.15%
- 10Y*
- —
ACXP
- 1D
- -1.95%
- 1M
- -23.35%
- YTD
- -39.36%
- 6M
- -56.23%
- 1Y
- -86.27%
- 3Y*
- -69.14%
- 5Y*
- —
- 10Y*
- —
PGNY vs. ACXP - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
PGNY Progyny, Inc. | 2.34% | 48.87% | -53.60% | 19.36% | -38.13% | -15.19% |
ACXP Acurx Pharmaceuticals, Inc. | -39.36% | -84.71% | -78.75% | -3.77% | -7.90% | -27.37% |
Correlation
The correlation between PGNY and ACXP is 0.08, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.08 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.11 |
Correlation (All Time) Calculated using the full available price history since Jun 25, 2021 | 0.09 |
Fundamentals
PGNY:
$2.23B
ACXP:
$4.10M
PGNY:
$0.76
ACXP:
-$959.29
PGNY:
5.07
ACXP:
0.00
PGNY:
$1.29B
ACXP:
$0.00
PGNY:
$311.76M
ACXP:
$0.00
PGNY:
$108.11M
ACXP:
-$5.88M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
PGNY vs. ACXP — Risk / Return Rank
PGNY
ACXP
PGNY vs. ACXP - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Progyny, Inc. (PGNY) and Acurx Pharmaceuticals, Inc. (ACXP). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| PGNY | ACXP | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.91 | ||
| Sortino ratioReturn per unit of downside risk | +1.93 | ||
| Omega ratioGain probability vs. loss probability | 1.16 | 0.91 | +0.24 |
| Calmar ratioReturn relative to maximum drawdown | 0.60 | -0.97 | +1.56 |
| Martin ratioReturn relative to average drawdown | 1.27 | -1.25 | +2.52 |
Loading charts...
Drawdowns
PGNY vs. ACXP - Drawdown Comparison
The maximum PGNY drawdown since its inception was -79.49%, smaller than the maximum ACXP drawdown of -99.14%. Use the drawdown chart below to compare losses from any high point for PGNY and ACXP.
Loading charts...
Drawdown Indicators
| PGNY | ACXP | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -79.49% | -99.14% | +19.65% |
Max Drawdown (1Y)Largest decline over 1 year | -42.65% | -89.26% | +46.61% |
Max Drawdown (3Y)Largest decline over 3 years | -68.14% | -98.83% | +30.69% |
Max Drawdown (5Y)Largest decline over 5 years | -79.49% | — | — |
Current DrawdownCurrent decline from peak | -60.58% | -99.04% | +38.46% |
Average DrawdownAverage peak-to-trough decline | -42.48% | -69.51% | +27.03% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 19.90% | 69.15% | -49.25% |
Volatility
PGNY vs. ACXP - Volatility Comparison
The current volatility for Progyny, Inc. (PGNY) is 8.52%, while Acurx Pharmaceuticals, Inc. (ACXP) has a volatility of 12.17%. This indicates that PGNY experiences smaller price fluctuations and is considered to be less risky than ACXP based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| PGNY | ACXP | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 8.52% | 12.17% | -3.65% |
Volatility (6M)Calculated over the trailing 6-month period | 41.34% | 119.74% | -78.40% |
Volatility (1Y)Calculated over the trailing 1-year period | 56.84% | 188.57% | -131.73% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 56.05% | 140.92% | -84.87% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 62.08% | 140.92% | -78.84% |
Dividends
PGNY vs. ACXP - Dividend Comparison
Neither PGNY nor ACXP has paid dividends to shareholders.
Financials
PGNY vs. ACXP - Financials Comparison
This section allows you to compare key financial metrics between Progyny, Inc. and Acurx Pharmaceuticals, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
PGNY and ACXP have a correlation of 0.08, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
ACXP has higher volatility (12.17%) compared to PGNY (8.52%). In terms of maximum drawdown, PGNY dropped -79.49% vs ACXP's -99.14%.
PGNY currently has the higher Sharpe Ratio (0.45 vs -0.46), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for PGNY and ACXP
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer